linjc16/ctgov huggingface dataset:
Exercise Influence on COVID-19

Study Overview
=================
Brief Summary
-----------------
An observational study is carried out in the university population of the University of Salamanca to know the impact of the COVID-19 pandemic and the influence of physical exercise on the severity of symptoms.

Detailed Description
-----------------
Investigate the relationship between the regular practice of moderate physical exercise and the severity of the COVID-19 disease in the university community of the University of Salamanca. Prepare an epidemiological study of the impact of the pandemic at the University of Salamanca. Analyze the influence of the pandemic on the sports habits of the university community. The study population will be the entire university community (teaching and research staff, administration and services staff, and students) who will be contacted via email.

Official Title
-----------------
Influence of Physical Exercise on the Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, COVID-19

Conditions
-----------------
Infection Viral, Exercise, Coronavirus, Habits

Intervention / Treatment
-----------------
* Diagnostic Test: COVID-19 survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: University of Salamanca population Complete the survey Exclusion Criteria: Survey not filled out completely

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| University population<br>Survey to analyze the impact of COVID-19. | Diagnostic Test: COVID-19 survey<br>* Participants should complete a survey to analyze the impact of COVID-19 on University population.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of COVID-19 | Number of positives | Through study completion, an average of 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Influence of exercise in COVID-19 infection | Quantity of physical exercise | Through study completion, an average of 3 months | 
| Change in the practice of physical exercise after home confinement | Change at exercise habits on University population | Through study completion, an average of 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise, Universities, Coronavirus, Habits
Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men

Study Overview
=================
Brief Summary
-----------------
The study will evaluate the pharmacokinetics of testosterone transdermal systems at steady-state in hypogonadal men.

Detailed Description
-----------------
Subjects will receive testosterone for 4 weeks. Based on a single morning testosterone measurement performed at the end of Week 1, the dosage can be titrated up or down to the next dose level to maintain testosterone levels in the normal range. At the end of 4 weeks of treatment, a pharmacokinetic profile for total testosterone and metabolites will be obtained.

Official Title
-----------------
An Open Label, Dose-Titration Investigation of the Pharmacokinetics, Metabolism and Safety of Testosterone Transdermal Systems in Hypogonadal Men

Conditions
-----------------
Hypogonadism

Intervention / Treatment
-----------------
* Drug: Testerone Transdermal System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males in good general health, 18 years of age or older. Have a previously documented testosterone deficiency. Willing and able to comply with the requirements of the protocol. Exclusion Criteria: Have a history of intolerance to Androderm or other testosterone products. Prostate specific antigen (PSA) level ≥ 4.0 ng/mL Prostate cancer or severe benign prostatic hypertrophy (BPH) Have significant abnormalities in the physical examination at screening. Have current dermatological disease, skin damage or blemishes. Have participated in an investigational drug study within 30 days prior to screening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Testosterone Transdermal Systems<br>Testosterone | Drug: Testerone Transdermal System<br>* Transdermal testosterone applied daily for 4 weeks<br>* Other names: Testosterone;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time-average (Cavg) Steady State Testosterone Concentration Over 24 Hours | A 24-hour pharmacokinetic sampling was performed on Day 28/29 after the start of dosing. | Day 28/29 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypogonadism, Testosterone, Hormone replacement therapy
Outcomes of Patients With Venoarterial Extracorporeal Membrane Oxygenation

Study Overview
=================
Brief Summary
-----------------
Venoarterial extracorporeal membrane oxygenation (VA ECMO)-also referred to as extracorporeal life support-is a form of temporary mechanical circulatory support and simultaneous extracorporeal gas exchange. The objective of this observational, cohort study is to evaluate the short-term and long-term outcomes of patients with VA ECMO.

Official Title
-----------------
Outcomes of Patients With Venoarterial Extracorporeal Membrane Oxygenation

Conditions
-----------------
Cardiogenic Shock, Cardiac Arrest

Intervention / Treatment
-----------------
* Device: VA ECMO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients receiving VA ECMO for cardiopulmonary support Exclusion Criteria: Refusal of consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ECMO<br> | Device: VA ECMO<br>* VA ECMO for cardiopulmonary support<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality |  | 365 days | 
| Rate of successful weaning from ECMO |  | 30 days | 
| ECMO-related complications | Bleeding requiring transfusion or surgery, stroke, sepsis, limb ischemia requiring intervention, system or cannula change | 30 days | 
| Other complications | Acute renal failure, ulcer bleeding, pneumonia, sepsis | 30 days | 
| Duration stay at ICU and hospital |  | 365 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
extracorporeal life support, extracorporeal membrane oxygenation, cardiogenic shock, cardiac arrest
A Trial of a Modified Cystoscopy Method to Reduce Pain Perception

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to improve patient experience of cystoscopy using a non-pharmacologic modification of procedure. Cystoscopy is a common outpatient procedure for urology patients and is usually performed without sedation. However, there is limited research into reduction of patient discomfort throughout this procedure. The proposed modification technique was selected based on a well-documented psychological phenomenon in which only particular moments over the course of an aversive event determine the resultant perception of the experience. It is hypothesized that implementation of the technique will decrease the recalled pain intensity of the cystoscopy.

Official Title
-----------------
A Randomized Control Trial of a Modified Cystoscopy Method to Reduce Pain Perception

Conditions
-----------------
Hematuria, Bladder Cancer, Bladder Disease

Intervention / Treatment
-----------------
* Behavioral: Modified Cystoscopy
* Behavioral: Routine Cystoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over the age of 18 undergoing cystoscopy for the first time for diagnostic investigation will be approached to participate in this study. Exclusion Criteria: Cystoscopies involving other interventions concurrently (e.g. biopsy, urethral dilation, removal of ureteral stent, etc.) will be excluded. Patients currently taking medication for chronic pain (e.g. opioids, Tricyclic antidepressants (TCAs)) will be excluded from the study. Patients less than 18 years of age will be excluded. Patients who have received a cystoscopy previously will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Routine Cystoscopy<br> | Behavioral: Routine Cystoscopy<br>* Routine cystoscopy as done as part of routine clinical practice<br>|
| Experimental: Modified Cystoscopy<br> | Behavioral: Modified Cystoscopy<br>* The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Experience rated on the visual analogue scale | The primary outcome of the study will be pain experience, as rated on the visual analogue scale provided. | 1 hour |
Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Study Overview
=================
Brief Summary
-----------------
Adherence to the prescribed treatment regimen with PegIntron and Rebetol affects the chance of achieving a sustained virologic response in patients with hepatitis C. The objective of this study is to evaluate the proportion of patients who complete treatment with PegIntron pen and Rebetol while participating in a patient assistance program. The patient assistance program can consist of prophylactic treatment (eg, with growth factors, psychiatric medications) or other interventions (eg, psychotherapy, patient support groups, visiting nurse, nurse telephone calls, educational literature).

Official Title
-----------------
Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C

Conditions
-----------------
Hepatitis C, Chronic, Hepatitis C

Intervention / Treatment
-----------------
* Biological: PegIntron pen (peginterferon alfa-2b; SCH 54031)
* Drug: Rebetol (ribavirin; SCH 18908)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treatment-naïve patients with hepatitis C Patients treated with PegIntron pen and Rebetol Patients receiving patient assistance program Exclusion Criteria: Not applicable
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Treated Patients<br>All patients participating in the study | Biological: PegIntron pen (peginterferon alfa-2b; SCH 54031)<br>* PegIntron administered in accordance with approved labeling.<br>* Other names: SCH 54031;Drug: Rebetol (ribavirin; SCH 18908)<br>* Rebetol administered in accordance with approved labeling<br>* Other names: SCH 18908;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Subjects Who Completed Treatment. |  | Assessed at the end of the 48-week treatment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Length of Treatment. |  | Assessed at the end of treatment. The prescribed treatment duration was 48 weeks. |
Genetics of Periodontal Diseases in Chinese (Taiwan)

Study Overview
=================
Brief Summary
-----------------
A retrospective case control study to validate the association between Interleukin-1 gene variations and adult chronic periodontal disease in Chinese (Taiwan).

Official Title
-----------------
The Association Between Interleukin-1 Gene Variations and Adult Chronic Periodontal Disease in Chinese (Taiwan))

Conditions
-----------------
Periodontal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be included in this study, an individual needs to be Han Chinese of 35 years of age or older at time of enrollment. Exclusion Criteria: Subjects who, at time of enrollment, were pregnant or breastfeeding, or needed antibiotic prophylaxis before periodontal treatment will be excluded from this study.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Yellow Versus White Study

Study Overview
=================
Brief Summary
-----------------
Blue-light-filtering IOLs are implanted increasingly often in cataract surgery. Several studies examined the effect of blue-light-filters on contrast and colour vision. However, the study outcomes were varying. The present study investigated the effect of a blue-light-filtering IOL on colour perception and contrast acuity using highly sensitive measurement methods.

Official Title
-----------------
Influence of Blue-Light-Filter IOLs on Color Perception and Contrast Acuity. A Randomized, Double-Masked Study With Intraindividual Comparison.

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Procedure: cataract surgery (Hoya AF-1 [UY] YA-60BB)
* Procedure: cataract surgery (Hoya AF-1 [UV] VA-60BB lens)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bilateral age-related cataract age 55 to 80 years expected postoperative visual acuity of at least 1.0 Exclusion Criteria: amblyopia corneal scars diabetes arterial hypertonia pseudoexfoliation-syndrome earlier ocular surgeries or laser treatments intraocular tumors color abnormalities expected postoperative visual acuity lower 1.0

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: A<br> | Procedure: cataract surgery (Hoya AF-1 [UY] YA-60BB)<br>* implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens<br>* Other names: Hoya AF-1 (UY) YA-60BB;|
| Other: B<br> | Procedure: cataract surgery (Hoya AF-1 [UV] VA-60BB lens)<br>* implantation of an uncoloured Hoya AF-1 (UV) VA-60BB<br>* Other names: Hoya AF-1 (UV) VA-60BB;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| contrast sensitivity |  | 3 month after surgery | 
| color vision |  | 3 month after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual acuity |  | 3 month after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intraocular lens, blue-light filtering intraocular lens, contrast acuity, color vision
Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion

Study Overview
=================
Brief Summary
-----------------
Propofol is a popular intravenous drug to induce anesthesia but it causes local pain with an incidence between 40 and 90%. Three different strategies to prevent propofol induced pain will be studied compared with placebo. Pain will be scored with a four-point scale.

Official Title
-----------------
Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion

Conditions
-----------------
Induction of Total Intravenous General Anesthesia

Intervention / Treatment
-----------------
* Drug: kétamine 20mg
* Drug: ephedrine 3mg
* Drug: lidocaine 40mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults (ASA 1-2) for scheduled surgery under general anesthesia with propofol Exclusion Criteria: pregnant sedative or analgesic drug 24h before surgery allergy with drug used in the study difficulty of communication absence of informed written consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: kétamine 20mg|nan|
|Drug: ephedrine 3mg|nan|
|Drug: lidocaine 40mg|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| After prophylactic solution, evaluation of the pain caused by injection of propofol with a four-point scale before lose of consciousness |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Explicite and implicite memory of pain immediately after surgery and on day one |  |  | 
| Adverse effects |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Propofol, pain, general anesthesia, prevention
Surgical Treatment of Early Stage Glotto-supraglottic Laryngeal Cancer Via Transoral Resection With Robotic Assistance

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to determine the rate of healthy surgical margins after tumor resection in transoral robot-assisted surgery for glottic and/or supraglottic early stage (T1-T2) laryngeal cancer.

Official Title
-----------------
Observational Study on Surgical Treatment of Early Stage (T1-T2) Glotto-supraglottic Laryngeal Cancer Via Transoral Resection With Robotic Assistance

Conditions
-----------------
Laryngeal Neoplasms

Intervention / Treatment
-----------------
* Procedure: Transoral robot-assisted tumor resection using the da Vinci robot


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject has signed consent The subject must be a member or beneficiary of a health insurance plan The patient is available for 12 months of follow-up The subject has a cancer of the larynx: classified T1 or T2 in the TNM glottic localization and / or supraglottic regardless of node status with or without a history of head and neck cancer The subject does not have distant metastasis (M0) A decision for endoscopic robot-assisted surgery is retained in multidisciplinary meeting Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| The study population<br>Laryngeal cancer patients requiring surgical tumor resection. | Procedure: Transoral robot-assisted tumor resection using the da Vinci robot<br>* Transoral robot-assisted tumor resection using the da Vinci robot<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The presence/absence of cancerous tissue in the surgical margins of the resectioned tumors |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to prepare the surgical setting (min) |  | 1 day | 
| Time necessary to dock the robot (min) |  | 1 day | 
| Total surgical time (console time) (min) |  | 1 day | 
| Intervention time taking into account cervical ganglions (min) |  | 1 day | 
| Was a tracheotomy necessary? yes/no |  | 1 day | 
| Presence / absence of bleeding complications |  | 1 day | 
| Was a conversion to an open procedure necessary? yes/no |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
da Vinci surgical robot, laryngeal cancer